IAN
VTGN icon

Integrated Advisors Network’s VistaGen Therapeutics VTGN Stock Holding History

Integrated Advisors Network’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-333
Closed -$9K – 699
2022
Q2 		$9K Sell
333
-250
-43% -$8.83K ﹤0.01% 658
2022
Q1 		$22K Hold
583
– – ﹤0.01% 654
2021
Q4 		$34K Hold
583
– – ﹤0.01% 616
2021
Q3 		$48K Sell
583
-150
-20% -$13K ﹤0.01% 601
2021
Q2 		$69K Hold
733
– – 0.01% 571
2021
Q1 		$47K Buy
733
+233
+47% +$15.6K ﹤0.01% 535
2020
Q4 		$29K Buy
+500
New +$12.8K ﹤0.01% 495

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Integrated Advisors Network's VTGN Position: Q3 2022 in Review

Integrated Advisors Network sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 333 shares — an estimated $9K sold.

Integrated Advisors Network first reported a position in VTGN in Q4 2020 and held it in 7 quarters. The position peaked at $69K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Integrated Advisors Network reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Integrated Advisors Network sold 333 VistaGen Therapeutics shares in Q3 2022, an estimated $9K.
  • Integrated Advisors Network first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 7 quarters.
  • Integrated Advisors Network's VistaGen Therapeutics position peaked at $69K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Integrated Advisors Network's 13F filing for Q3 2022, filed 8 Nov 2022.